Using a new antibody to improve prostate cancer immunotherapy
Immunotherapy of prostate cancer using an anti-CD6 monoclonal antibody
['FUNDING_R21'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11036348
This study is exploring a new way to boost immunotherapy for prostate cancer by using a special antibody that targets a protein called CD6, which could help immune cells better fight the cancer, and patients may have the chance to participate in trials to see how safe and effective this treatment is.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11036348 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to enhance immunotherapy for prostate cancer by targeting the CD6 protein, which plays a crucial role in T-lymphocyte interactions. The study aims to develop an anti-CD6 monoclonal antibody that can potentially improve the infiltration of immune cells into the tumor microenvironment, overcoming current limitations of existing treatments. By blocking the CD6-CD318 interaction, the research seeks to enable lymphocytes to effectively attack prostate cancer cells. Patients may be involved in trials to assess the safety and efficacy of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients diagnosed with prostate cancer who have not responded well to existing immunotherapy treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone any form of immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for prostate cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: While the approach of targeting the CD6-CD318 axis is relatively novel, previous studies have shown promise in using similar immunotherapy strategies for other autoimmune conditions.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FOX, DAVID ALAN — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: FOX, DAVID ALAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer immunotherapy, anti-cancer therapy